openFDA
Cure8 regulatory brief
mesalamine FDA label update (2026-07-14)
Medications
Mesalamine
Aminosalicylates
Anemia
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Why This Matters
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.
If you or a caregiver use mesalamine, the update underscores actions clinicians may take (baseline and periodic renal tests, stopping the drug if certain problems arise).
Who Should Pay Attention
Adults with ulcerative colitis prescribed mesalamine; clinicians who prescribe or monitor mesalamine; caregivers of patients on mesalamine.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA DailyMed label update for mesalamine delayed‑release tablets (an aminosalicylate) describing indications, limitations of use, and safety warnings added or clarified in the prescribing information.
The label emphasizes assessing and monitoring renal function before and during treatment, and discontinuing mesalamine if renal function deteriorates.
It also highlights mesalamine‑induced acute intolerance syndrome that can mimic a worsening of ulcerative colitis, hypersensitivity reactions (including myocarditis/pericarditis), hepatic adverse events, severe cutaneous reactions (SJS/TEN/DRESS), photosensitivity, and reports of nephrolithiasis.
It advises clinicians to evaluate risks/benefits in patients with renal or hepatic impairment and to monitor for specific adverse signs. Read the updated full label or discuss with your clinician for how these warnings apply to your situation.
Keep In Mind
Structured content depth: regulatory-record. This entry summarizes the updated prescription drug labeling from DailyMed (FDA). It reflects warnings and monitoring recommendations in the label; it is not clinical guidance and does not replace advice from a healthcare professional.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorZydus Pharmaceuticals USA Inc.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 14, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Rescue Vedolizumab Therapy for a Rare Case of Complicated Severe Ulcerative Colitis: A Case Report and Literature Review.
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
DailyMed label update for RINVOQ
A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...